药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Apraclonidine
Astaxanthin
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Astaxanthin.
Apraclonidine
Cangrelor
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Cangrelor.
Apraclonidine
Idraparinux
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Idraparinux.
Apraclonidine
Sulodexide
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Sulodexide.
Apraclonidine
Rivaroxaban
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Rivaroxaban.
Apraclonidine
Prasugrel
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Prasugrel.
Apraclonidine
Fibrinolysin
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Fibrinolysin.
Apraclonidine
Beraprost
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Beraprost.
Apraclonidine
Ancrod
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Ancrod.
Apraclonidine
Defibrotide
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Defibrotide.
Apraclonidine
Desmoteplase
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Desmoteplase.
Apraclonidine
Ximelagatran
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Ximelagatran.
Apraclonidine
Coumarin
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Coumarin.
Apraclonidine
4-hydroxycoumarin
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with 4-hydroxycoumarin.
Apraclonidine
Epoprostenol
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Epoprostenol.
Apraclonidine
Enoxaparin
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Enoxaparin.
Apraclonidine
Heparin
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Heparin.
Apraclonidine
Monteplase
The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Monteplase.
Apraclonidine
Camostat
Camostat may increase the thrombogenic activities of Platelet Activating Factor.
Apraclonidine
Aminomethylbenzoic acid
Aminomethylbenzoic acid may increase the thrombogenic activities of Platelet Activating Factor.